AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37016357 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sleep duration
Number of subjects: 3291
Study 37016357 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-school learning time
Number of subjects: 3291
Study 37016357 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor time (exceeding 2.3 hours per day)
Number of subjects: 3291
Study 37016357 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor time, sleep duration, and out-of-school learning time
Number of subjects: 3291
Study 37016372 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy School Start Plus (HSSP) intervention
Number of subjects: 20
Study 37016392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) - weekly single-day courses
Number of subjects: 824
Study 37016392 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP) - monthly single-day courses
Number of subjects: 824
Study 37016392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 824
Study 37016394 — intervention group
Group type: EXPERIMENTAL
Intervention: MOUD with adjunctive use of OptiMAT (MOUD+OptiMAT)
Number of subjects: 0
Study 37016394 — intervention group
Group type: COMPARATOR
Intervention: MOUD without OptiMAT (MOUD-only)
Number of subjects: 0
Study 37016454 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 100
Study 37016454 — intervention group
Group type: COMPARATOR
Intervention: High tibial osteotomy (HTO)
Number of subjects: 100
Study 37016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 1-19 steps
Number of subjects: 82
Study 37016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 20-39 steps
Number of subjects: 82
Study 37016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 40-59 steps
Number of subjects: 82
Study 37016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 60-79 steps
Number of subjects: 82
Study 37016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 80-99 steps
Number of subjects: 82
Study 37016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of ≥100 steps
Number of subjects: 82
Study 37016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Longest daily sustained walking bout at 1-19 steps
Number of subjects: 82
Study 37016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouts lasting 20 minutes and greater
Number of subjects: 82
Study 37016622 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 physical component summary (PCS)
Number of subjects: 276
Study 37016622 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 mental component summary (MCS)
Number of subjects: 276
Study 37016622 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-VAS
Number of subjects: 276
Study 37016808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular cups fixated with 1 screw
Number of subjects: 68
Study 37016808 — intervention group
Group type: COMPARATOR
Intervention: Acetabular cups fixated with no screws
Number of subjects: 68
Study 37016808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular cups fixated with 2 screws
Number of subjects: 68
Study 37016906 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg oral daily and bevacizumab 15 mg/kg intravenously on day 1, repeated every 21 days until disease progression, intolerable toxicity, or death
Number of subjects: 52
Study 37017254 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab plus standard therapy (ST)
Number of subjects: 0
Study 37017254 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST) alone
Number of subjects: 0
Study 37017254 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab plus ST
Number of subjects: 0
Study 37017401 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation intervention (four relaxation sessions)
Number of subjects: 0
Study 37017401 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 0
Study 37017468 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Bolus Calculator
Number of subjects: 0
Study 37017468 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 37017470 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased derived time in range (dTIR)
Number of subjects: 0
Study 37017631 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir (MOV)
Number of subjects: 1313
Study 37017631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1313
Study 37017634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough stimulation system (CSS)
Number of subjects: 15
Study 37017737 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Number of subjects: 66
Study 37017737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 37017765 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole wheat bread enriched with hydroxytyrosol (HTB)
Number of subjects: 60
Study 37017765 — intervention group
Group type: COMPARATOR
Intervention: Conventional whole wheat bread (WWB)
Number of subjects: 60
Study 37017900 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative quantitative flow ratio (QFR) assessment
Number of subjects: 54
Study 37017900 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-functional bypass grafts
Number of subjects: 54
Study 37017967 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation (IF)
Number of subjects: 756
Study 37018024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum NCC3001 (probiotic) during pregnancy and postpartum (from 28-32 weeks' gestation until 12 weeks after delivery)
Number of subjects: 180
Study 37018024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum NCC3001 (probiotic) postpartum only (from birth until 12 weeks after delivery)
Number of subjects: 180
Study 37018024 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 180
Study 37018064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (oral administration)
Number of subjects: 7
Study 37018188 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt glucocorticoid stop
Number of subjects: 573
Study 37018188 — intervention group
Group type: COMPARATOR
Intervention: Tapering doses of prednisone
Number of subjects: 573
Study 37018188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study 37018188 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH-test
Number of subjects: 573
Study 37018188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoid doses
Number of subjects: 573
Study 37018188 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs and symptoms of hypocortisolism
Number of subjects: 573
Study 37018234 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan treatment in lymphoblastoid cell lines (LCLs)
Number of subjects: 87
Study 37018234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of expression experiment and WES data analysis
Number of subjects: 87
Study 37018415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR)-T cells enriched in memory T cells
Number of subjects: 0
Study 37018415 — intervention group
Group type: COMPARATOR
Intervention: Standard CAR-T cells (not enriched in memory T cells)
Number of subjects: 0
Study 37018468 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF vaccine (120 μg)
Number of subjects: 34284
Study 37018468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34284
Study 37018474 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent RSV prefusion F protein-based vaccine (120 μg, single intramuscular injection)
Number of subjects: 3682
Study 37018492 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2-CART01
Number of subjects: 27
Study 37018493 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 501
Study 37018493 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 501
Study 37018649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid maintenance therapy with panitumumab
Number of subjects: 377
Study 37018649 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and folinic acid maintenance therapy without panitumumab
Number of subjects: 377
Study 37018790 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 14 days
Number of subjects: 0
Study 37018790 — intervention group
Group type: COMPARATOR
Intervention: Local standard treatment alone
Number of subjects: 0
Study 37018802 — intervention group
Group type: EXPERIMENTAL
Intervention: EHP with Efferon LPS
Number of subjects: 58
Study 37018802 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional protocols without EHP)
Number of subjects: 58
Study 37018848 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and BCAA supplementation
Number of subjects: 120
Study 37018848 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only
Number of subjects: 120
Study 37018848 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation-only
Number of subjects: 120
Study 37018848 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 37018968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigileo/FloTrac-guided hydration
Number of subjects: 344
Study 37018968 — intervention group
Group type: COMPARATOR
Intervention: General hydration (control)
Number of subjects: 344
Study 37019044 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus a newly initiated oral antidepressant (ESK+AD)
Number of subjects: 518
Study 37019044 — intervention group
Group type: COMPARATOR
Intervention: Newly initiated oral antidepressant plus placebo nasal spray (AD+PBO)
Number of subjects: 518
Study 37019077 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB dose >0%-25%
Number of subjects: 4800
Study 37019077 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB dose >25%
Number of subjects: 4800
Study 37019077 — intervention group
Group type: COMPARATOR
Intervention: ARB dose ≤25%
Number of subjects: 4800
Study 37019077 — intervention group
Group type: COMPARATOR
Intervention: No ARB
Number of subjects: 4800
Study 37019180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-free sugar diet (LFSD)
Number of subjects: 140
Study 37019180 — intervention group
Group type: COMPARATOR
Intervention: Usual diet + educational materials
Number of subjects: 140
Study 37019195 — intervention group
Group type: EXPERIMENTAL
Intervention: WatchPAT home sleep testing (HST) for OSA
Number of subjects: 38
Study 37019309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mobility bearings (DM)
Number of subjects: 146
Study 37019309 — intervention group
Group type: COMPARATOR
Intervention: Large femoral heads (≥36 mm)
Number of subjects: 146
Study 37019334 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose erythropoietin (Epo)
Number of subjects: 500
Study 37019334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 37019352 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-to-pelvis sudden death CT (SDCT) scan within 6 hours of hospital arrival
Number of subjects: 247
Study 37019352 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 247
Study 37019355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model PLUS-M for lung cancer staging-mediastinal metastasis
Number of subjects: 589
Study 37019355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model PLUS-E for mediastinal metastasis detection by EBUS-TBNA
Number of subjects: 589
Study 37019355 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort for PLUS-M
Number of subjects: 589
Study 37019355 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort for PLUS-E
Number of subjects: 589
Study 37019355 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 589
Study 37019361 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-Lancet reference diet adherence (measured by EAT-Lancet Diet Index - ELD-I)
Number of subjects: 98465
Study 37019361 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-Lancet reference diet adherence (measured by ELD-I)
Number of subjects: 98465
Study 37019367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab with Definitive Radiation Therapy
Number of subjects: 0
Study 37019367 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37019443 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g IV tranexamic acid (TXA)
Number of subjects: 120
Study 37019443 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g IM tranexamic acid (TXA)
Number of subjects: 120
Study 37019443 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g oral tranexamic acid (TXA)
Number of subjects: 120
Study 37019443 — intervention group
Group type: COMPARATOR
Intervention: No TXA (Control)
Number of subjects: 120
Study 37019445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 37019471 — intervention group
Group type: EXPERIMENTAL
Intervention: CF33-hNIS-antiPDL1 (intraperitoneal treatment)
Number of subjects: 6
Study 37019471 — intervention group
Group type: EXPERIMENTAL
Intervention: CF33-OVs (intraperitoneal treatment)
Number of subjects: 6
Study 37019486 — intervention group
Group type: EXPERIMENTAL
Intervention: biparametric MRI (bpMRI)
Number of subjects: 500
Study 37019486 — intervention group
Group type: COMPARATOR
Intervention: multiparametric MRI (mpMRI)
Number of subjects: 500
Study 37019487 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHRU-CPP intervention (6-month self-management program including home and phone visits, care coordination, system navigation support, caregiver support, and group wellness sessions)
Number of subjects: 45
Study 37019491 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless physical activity monitor (WPAM)
Number of subjects: 80
Study 37019582 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged moderate-intensity exercise (30, 40, or 50 km/d for 4 consecutive days)
Number of subjects: 100
Study 37019582 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged moderate-intensity exercise
Number of subjects: 100
Study 37019582 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte CoQ10 levels
Number of subjects: 100
Study 37019619 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 therapy
Number of subjects: 0
Study 37019619 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARγ/VEGF-A-mediated TME immunosuppression
Number of subjects: 0
Study 37019619 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II trial of pembrolizumab (NCT03419481)
Number of subjects: 0
Study 37019764 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab + BSC
Number of subjects: 147
Study 37019764 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 147
Study 37019807 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 226
Study 37019821 — intervention group
Group type: EXPERIMENTAL
Intervention: RhoA/Rho-kinase inhibitor (fasudil)
Number of subjects: 37
Study 37019821 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 arteries (no specific intervention mentioned)
Number of subjects: 37
Study 37019892 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem-cells transduced with the Lenti-D lentiviral vector containing ABCD1 cDNA
Number of subjects: 0
Study 37019892 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem cell transplantation
Number of subjects: 0
Study 37019987 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-CT
Number of subjects: 0
Study 37019987 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-[
Number of subjects: 0
Study 37020027 — intervention group
Group type: EXPERIMENTAL
Intervention: AI cardiac function assessment
Number of subjects: 0
Study 37020027 — intervention group
Group type: COMPARATOR
Intervention: Sonographer cardiac function assessment
Number of subjects: 0
Study 37020098 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot balloon palpation for cuff pressure assessment
Number of subjects: 208
Study 37020098 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube ID 6.0
Number of subjects: 208
Study 37020098 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube ID 8.0
Number of subjects: 208
Study 37020172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hood PPE (n = 20)
Number of subjects: 40
Study 37020172 — intervention group
Group type: COMPARATOR
Intervention: Standard PPE (n = 20)
Number of subjects: 40
Study 37020200 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-governmental orphanage
Number of subjects: 156
Study 37020200 — intervention group
Group type: EXPERIMENTAL
Intervention: Governmental orphanage
Number of subjects: 156
Study 37020200 — intervention group
Group type: COMPARATOR
Intervention: Parented school children
Number of subjects: 156
Study 37020274 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditators (Samyama program with vegan diet)
Number of subjects: 288
Study 37020274 — intervention group
Group type: COMPARATOR
Intervention: Household controls
Number of subjects: 288
Study 37020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain severity
Number of subjects: 317
Study 37020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain > 2 years of evolution
Number of subjects: 317
Study 37020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain interference
Number of subjects: 317
Study 37020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain > 2 years
Number of subjects: 317
Study 37020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression severity
Number of subjects: 317
Study 37020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational status as active worker
Number of subjects: 317
Study 37020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Currently working
Number of subjects: 317
Study 37020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 317
Study 37020259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes
Number of subjects: 3269
Study 37020259 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibodies against type I IFN
Number of subjects: 3269
Study 37020259 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2-infected individuals without pneumonia
Number of subjects: 3269
Study 37020315 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS (transjugular intrahepatic portosystemic shunt)
Number of subjects: 100
Study 37020315 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (terlipressin and albumin)
Number of subjects: 100
Study 37020315 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 100
Study 37020570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefecon plus Best Supportive Care (BSC)
Number of subjects: 0
Study 37020570 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study 37020805 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation at 500 mg/day
Number of subjects: 0
Study 37020805 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37020837 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Diagnostic Profiling (ADPro) substudy using novel functional imaging and physiological assessments
Number of subjects: 180
Study 37020837 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological assessments of pulmonary function including spirometry, bronchodilator reversibility, static lung volumes
Number of subjects: 180
Study 37020840 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg d-cycloserine
Number of subjects: 72
Study 37020840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 37020926 — intervention group
Group type: EXPERIMENTAL
Intervention: Socazolimab (5 mg/kg) every three weeks, Carboplatin (AUC: 5) every three weeks, Etoposide (100 mg/m2) every three weeks
Number of subjects: 20
Study 37020926 — intervention group
Group type: EXPERIMENTAL
Intervention: Socazolimab, Carboplatin, and Etoposide
Number of subjects: 20
Study 37021137 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 26
Study 37021137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 26
Study 37021164 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged home (intervention group)
Number of subjects: 3184
Study 37021164 — intervention group
Group type: COMPARATOR
Intervention: Discharged elsewhere (control group)
Number of subjects: 3184
Study 37021164 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged home (intervention group) after confounding adjustment
Number of subjects: 3184
Study 37021164 — intervention group
Group type: COMPARATOR
Intervention: Discharged elsewhere (control group) after confounding adjustment
Number of subjects: 3184
Study 37021170 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized educational talk (SET) on intravenous thrombolysis (IVT)
Number of subjects: 0
Study 37021189 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 3
Study 37021189 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 3
Study 37021189 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 3
Study 37021284 — intervention group
Group type: EXPERIMENTAL
Intervention: Astrocyte-derived exosomes (ADEs) in the SCD group
Number of subjects: 125
Study 37021284 — intervention group
Group type: COMPARATOR
Intervention: Plasma levels of IL-6, IL-8, and MCP-1
Number of subjects: 125
Study 37021333 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root debridement
Number of subjects: 44
Study 37021333 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study 37021342 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Up NHR trajectory
Number of subjects: 1013